Novartis Ag Adr Stock Beta
| NVS Stock | USD 94.41 0.89 0.95% |
Novartis AG ADR fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Stock. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis stock.
Novartis | Beta |
Novartis AG ADR Company Beta Analysis
Novartis' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Novartis Beta | 0.48 |
Most of Novartis' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novartis Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Novartis is extremely important. It helps to project a fair market value of Novartis Stock properly, considering its historical fundamentals such as Beta. Since Novartis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novartis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novartis' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Novartis AG ADR has a Beta of 0.475. This is 44.77% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Novartis Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.Novartis is currently under evaluation in beta category among related companies.
Novartis Institutional Holders
Institutional Holdings refers to the ownership stake in Novartis that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Novartis' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Novartis' value.| Shares | Principal Financial Group Inc | 2023-12-31 | 2.5 M | Northern Trust Corp | 2023-12-31 | 2.1 M | Envestnet Asset Management Inc | 2023-12-31 | 2 M | Wells Fargo & Co | 2023-12-31 | 2 M | Blackrock Inc | 2023-12-31 | 1.8 M | State Street Corporation | 2023-12-31 | 1.8 M | Ubs Group Ag | 2023-12-31 | 1.7 M | Cullen Capital Management, Llc | 2023-12-31 | 1.6 M | Grantham, Mayo, Van Otterloo & Co., Llc | 2023-12-31 | 1.5 M | Dodge & Cox | 2023-12-31 | 13.2 M | Primecap Management Company | 2023-12-31 | 12.9 M |
As returns on the market increase, Novartis' returns are expected to increase less than the market. However, during the bear market, the loss of holding Novartis is expected to be smaller as well.
Novartis Fundamentals
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0727 | ||||
| Profit Margin | 0.32 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 203.61 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Shares Owned By Institutions | 6.92 % | ||||
| Number Of Shares Shorted | 4.21 M | ||||
| Price To Earning | 9.22 X | ||||
| Price To Book | 4.10 X | ||||
| Price To Sales | 4.14 X | ||||
| Revenue | 46.66 B | ||||
| Gross Profit | 36.74 B | ||||
| EBITDA | 18.47 B | ||||
| Net Income | 8.57 B | ||||
| Cash And Equivalents | 4.64 B | ||||
| Cash Per Share | 8.84 X | ||||
| Total Debt | 26.35 B | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 1.31 X | ||||
| Book Value Per Share | 22.83 X | ||||
| Cash Flow From Operations | 14.46 B | ||||
| Short Ratio | 2.77 X | ||||
| Earnings Per Share | 4.10 X | ||||
| Price To Earnings To Growth | 5.09 X | ||||
| Target Price | 113.76 | ||||
| Number Of Employees | 76.06 K | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 193.41 B | ||||
| Total Asset | 99.94 B | ||||
| Retained Earnings | 49.65 B | ||||
| Working Capital | 4.09 B | ||||
| Current Asset | 22.84 B | ||||
| Current Liabilities | 23.71 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 3.53 % | ||||
| Net Asset | 99.94 B | ||||
| Last Dividend Paid | 3.92 |
About Novartis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Novartis Investors Sentiment
The influence of Novartis' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novartis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novartis' public news can be used to forecast risks associated with an investment in Novartis. The trend in average sentiment can be used to explain how an investor holding Novartis can time the market purely based on public headlines and social activities around Novartis AG ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novartis' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novartis' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novartis' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novartis.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Novartis Piotroski F Score and Novartis Altman Z Score analysis. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.987 | Dividend Share 3.919 | Earnings Share 4.1 | Revenue Per Share 22.467 | Quarterly Revenue Growth 0.074 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.